Wholesale Retatrutide (LY3437943)
Triple GLP-1/GIP/Glucagon Agonist — Lyophilised Powder & Predosed Pens
Retatrutide (LY3437943) is an investigational triple receptor agonist peptide developed by Eli Lilly, simultaneously targeting the GLP-1, GIP, and glucagon receptors. This tri-agonist mechanism distinguishes it from both single GLP-1 agonists such as semaglutide and dual agonists such as tirzepatide, with Phase II data reporting among the highest weight reduction figures seen in any GLP-1 class agent to date. It is currently in Phase II/III clinical development for obesity and metabolic disease.
SARMs-Direct supplies wholesale Retatrutide in lyophilised powder and predosed pen formats to CROs, pharmaceutical R&D groups, universities, clinics, and qualified B2B distributors. All supply is strictly for research use only and is not available for human consumption or clinical use.
Compound Specifications
| Compound Name | Retatrutide |
| Development Code | LY3437943 |
| Compound Class | Triple Receptor Agonist Peptide (GLP-1 / GIP / Glucagon) |
| CAS Number | 2270038-40-3 |
| Developer | Eli Lilly and Company |
| Administration | Subcutaneous injection (weekly) |
| Development Status | Phase II / III (obesity & metabolic disease) |
| Purity | ≥98% (HPLC & MS verified) |
| Supply Form | Lyophilised powder in sterile vials; predosed pens |
| Storage | –20°C recommended for long-term storage. Temperature-controlled shipping available. |
Available Formats & MOQs
Lyophilised Powder (Sterile Vials)
MOQ: 1g. Bulk supply from 10g. Custom batch sizes available on request. Supplied in sterile, sealed vials. Vacuum-sealed and shipped with temperature control where required. Full COA, HPLC, and MS data included per batch.
Predosed Research Pens
Prefilled with sterile Retatrutide solution. Dial-a-dose mechanism for precision and repeatability. No vials, syringes, or manual reconstitution required. Contact us for dose concentrations, unit quantities, and MOQ.
Custom Batch Sizes
Available for both formats on request. Contact us with your target quantity, delivery location, and documentation requirements.
Research Context
Retatrutide's tri-agonist mechanism acts on three distinct metabolic receptors simultaneously. GLP-1 receptor agonism reduces appetite and slows gastric emptying. GIP receptor agonism enhances insulin secretion and may improve the tolerability profile of GLP-1 agonism. Glucagon receptor agonism increases hepatic glucose output and, importantly, increases energy expenditure — a mechanism not present in single or dual GLP-1 agonists.
This combined receptor activity is hypothesised to produce additive or synergistic effects on weight reduction and metabolic regulation. Phase II data has reported mean weight reductions of approximately 24% or greater at higher doses over 48 weeks — among the highest figures reported for any agent in this class to date. Research areas include obesity pharmacotherapy, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiometabolic risk factor reduction.
For oral GLP-1 pathway research alternatives, see our Orforglipron (LY3502970) page. For peptide-based weight management compounds, visit our sister site Peptide-Direct.
All data cited refers to publicly available clinical trial readouts. All products are supplied for research purposes only and are not intended for human or veterinary use. No claims of safety or efficacy are made.
Predosed Retatrutide Pens
Our predosed Retatrutide pens are designed to simplify accurate dosing in research settings. Each pen is prefilled with a sterile solution at a preset concentration, with a dial-a-dose mechanism that eliminates the need for manual vial reconstitution, syringes, and preparation steps.
- Prefilled with sterile Retatrutide solution
- Dial-a-dose mechanism for flexible, precise dosing
- No vials or syringes required — reduces handling steps
- Minimises contamination risk during research preparation
- Consistent, repeatable dosing across study cohorts
- Discreet design suitable for multi-site research programmes
Contact us for available dose concentrations, pen quantities, and pricing.
GLP-1 Pathway Agents — Research Comparison
| Compound | Mechanism | Format | Dev. Status |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon (triple) | Injectable (weekly) | Phase II/III |
| Orforglipron | GLP-1 agonist (small molecule) | Oral (daily) | Phase III |
| Tirzepatide | GLP-1 + GIP dual agonist (peptide) | Injectable (weekly) | Approved |
| Semaglutide | GLP-1 agonist (peptide) | Injectable (weekly) | Approved |
ⓘ For research reference only. Data is not directly comparable across studies or compounds.
Quality & Documentation
- GMP-certified manufacturing
- ISO quality management system
- HACCP-compliant production controls
- Independent third-party testing — HPLC, MS, ICP-MS
- Full analytical report (COA, HPLC, MS data) per batch
- Batch and lot traceability records
- Research Use Only labelling and export documentation included
- Temperature-controlled shipping available on request
See our Lab Testing & QA page for full methodology detail.
Who Orders Wholesale Retatrutide
- Contract Research Organisations (CROs) — obesity and metabolic disease research programmes
- University research groups — triple receptor agonist pharmacology studies
- Pharmaceutical R&D teams — comparator and reference compound supply
- Clinics & wellness businesses — GLP-1 pathway research programmes
- Qualified B2B distributors — specialist research peptide distribution
See our Industries We Serve page for full B2B client detail.
Shipping & Delivery
| Region | Delivery Time | Notes |
|---|---|---|
| 🇩🇪 🇳🇱 🇫🇷 EU | 2–4 business days | Tracked courier, temperature-controlled |
| 🇬🇧 UK & 🇺🇸 USA | 3–6 business days | Customs documentation provided |
| 🇨🇦 Canada | 4–8 business days | Additional import forms may apply |
| 🇦🇺 Australia | 7–12 business days | Import permits may be required |
See our Shipping & Logistics page for full country-by-country detail.
Related Compounds
- Orforglipron (LY3502970) — oral non-peptide GLP-1 agonist, no cold chain required
- Klotho — longevity and metabolic research compound, also available as predosed pens
- MK-677 (Ibutamoren) — oral growth hormone secretagogue, metabolic research applications
For peptide-based weight management and GLP-1 pathway compounds, visit our sister site Peptide-Direct.
Frequently Asked Questions
What is Retatrutide (LY3437943)?
Retatrutide is an investigational triple agonist peptide by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase II/III development for obesity and metabolic disease. Available for research use only.
What is the CAS number for Retatrutide?
The CAS number for Retatrutide is 2270038-40-3.
What formats is wholesale Retatrutide available in?
Lyophilised powder in sterile vials (MOQ 1g, bulk from 10g) and predosed research pens. Custom batch sizes available on request.
What are predosed Retatrutide pens?
Prefilled research delivery devices with a dial-a-dose mechanism. Eliminate the need for manual reconstitution and syringe preparation, reducing handling steps and contamination risk in research settings.
How does Retatrutide differ from semaglutide or tirzepatide?
Retatrutide adds glucagon receptor agonism to the GLP-1 and GIP activity seen in tirzepatide. This third mechanism increases energy expenditure — not just appetite suppression — which is associated with the notably high weight reduction figures seen in Phase II data.
Do you provide COAs for wholesale Retatrutide?
Yes. Full analytical reports including COA, HPLC, and MS data are included with every batch.
Legal & Safety Notice
Retatrutide is an investigational research compound. It is not approved by any regulatory authority for human consumption, medical treatment, or clinical application. All purchases are restricted to qualified institutional or professional B2B buyers. Buyers are responsible for ensuring compliance with applicable regulations in their jurisdiction.
Provide your organisation details, required quantity, and shipping destination for a tailored quotation.
